Abeona Therapeutics Inc. ABEO
Set alert
At close · Oct 30
After hours · Oct 30, 4:10 PM ET
- YTD
- -17.46%
- 1 year
- -14.37%
- Open
- 4.50
- Prev close
- 4.56
- Mkt cap
- 248.75M
- Vol
- 783.43K
- Avg vol
- 1.35M
- EPS
- -1.18
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.31
- High
- 4.53
- Forward P/E
- -3.84
- Beta
- 1.50
- Short ratio
- 10.79
- Inst. own
- 77.54%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 6.15
- 200-d avg
- 5.64
- 1y target
- 16.75
News
2 weeks ago defenseworld.net
Abeona Therapeutics Inc. (NASDAQ:ABEO) Stock Has Consensus Target Price of $21.00
Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six analysts that are presently covering the company, MarketBeat…
3 weeks ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are…
1 month ago globenewswire.com
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Ohio, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The…
1 month ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised…
1 month ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are…
1 month ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO).
1 month ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are…
1 month ago marketbeat.com
Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright
Abeona Therapeutics NASDAQ: ABEO highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB),…
1 month ago marketbeat.com
Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum
Abeona Therapeutics NASDAQ: ABEO executives outlined the early commercial rollout of ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB),…
1 month ago benzinga.com
Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday
Analysts downgraded XENE, NFLX and MGA, while raising price targets for OCS, INSW, ABEO and STNG.
1 month ago benzinga.com
Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week
Abeona Therapeutics Inc. (NASDAQ:ABEO) had a busy week that included a new treatment center activation, an FDA approval for a drug the company licensed away and multiple fresh analyst ratings.
1 month ago benzinga.com
Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week
Abeona Therapeutics had a busy week with treatment network expansion, an FDA approval tied to a licensed therapy and fresh analyst coverage.
1 month ago globenewswire.com
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
- FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona's foundational R&D and clinical development efforts -
-
1 month ago benzinga.com
Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $30
Cantor Fitzgerald analyst Kristen Kluska maintains Abeona Therapeutics (NASDAQ:ABEO) with a Overweight and raises the price target from $28 to $30.
-
1 month ago benzinga.com
Ultragenyx Pharmaceutical Says FDA Grants Standard Full Approval Of FAYUVI For Treatment Of Pediatric Patients With Mucopolysaccharidosis Type IIIA
FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the devastating, irreversible neurologic progression and loss of function associated with Sanfilippo…
1 month ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO).
-
1 month ago benzinga.com
Roth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Abeona Therapeutics (NASDAQ:ABEO) with a Buy rating and announces Price Target of $17.
1 month ago seekingalpha.com
Abeona Therapeutics Inc. (ABEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Abeona Therapeutics Inc. (ABEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago globenewswire.com
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet…
1 month ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO).
1 month ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO).
1 month ago businesswire.com
ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $ABEO--ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law.
1 month ago gurufocus.com
ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
1 month ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are…
1 month ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO).
-
2 months ago benzinga.com
Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21
Oppenheimer analyst Jeff Jones maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperform and lowers the price target from $22 to $21.
2 months ago benzinga.com
Abeona Therapeutics Q2 2026 Earnings Call Transcript
Abeona Therapeutics (NASDAQ:ABEO) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For…
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's pre-market session. The company's market cap stands at $7.2 million. LENSAR (NASDAQ:LNSR) shares…
-
2 months ago benzinga.com
Abeona Therapeutics Q2 EPS $(0.35) Misses $(0.23) Estimate, Sales $11.380M Miss $12.239M Estimate
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.23) by 52.17 percent. This is a 5.41 percent increase over losses…
-
2 months ago benzinga.com
Abeona Therapeutics Says CMS Granted New Technology Add-On Payment Status For ZEVASKYN Under Fiscal Year 2027 Hospital Inpatient Prospective Payment System Final Rule
The Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for ZEVASKYN (prademagene zamikeracel) under the Fiscal Year 2027 Hospital Inpatient…
-
3 months ago benzinga.com
Abeona Therapeutics Activates Cincinnati Children’s As Seventh Qualified Treatment Center For Administration Of ZEVASKYN To Treat Wounds In Patients With Recessive Dystrophic Epidermolysis Bullosa
Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the activation of Cincinnati Children’s…
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $20 price target.
-
5 months ago benzinga.com
Abeona Therapeutics Q1 2026 Earnings Call: Complete Transcript
Abeona Therapeutics Q1 2026 Earnings Call: Complete Transcript
5 months ago benzinga.com
Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network
Abeona Therapeutics Inc. (NASDAQ: ABEO) reported first-quarter earnings Wednesday before the market opened. Here's a rundown of the report.
-
5 months ago benzinga.com
Abeona Therapeutics Q1 EPS $(0.30) Beats $(0.35) Estimate, Sales $8.720M Beat $4.572M Estimate
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.35) by 14.29 percent. This is a 25 percent decrease over losses of…
-
5 months ago benzinga.com
Abeona Therapeutics Activates Children's Hospital Of Philadelphia As Sixth Qualified Treatment Center To Treat ZEVASKYN Gene-Modified Cellular Sheets
Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced activation of the…
-
7 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $20 price target.
-
7 months ago benzinga.com
Abeona Therapeutics Q4 EPS $(0.34) Beats $(0.36) Estimate, Sales $5.420M Beat $5.270M Estimate
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.36) by 4.49 percent. This is a 142.86 percent decrease over losses of…
-
7 months ago benzinga.com
Earnings Scheduled For March 17, 2026
Earnings Scheduled For March 17, 2026
-
7 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $20 price target.
11 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
11 months ago benzinga.com
Abeona Therapeutics Q3 EPS $(0.10) Beats $(0.29) Estimate
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.29) by 65.52 percent. This is a 84.13 percent increase over losses of…
-
11 months ago benzinga.com
Earnings Scheduled For November 12, 2025
Earnings Scheduled For November 12, 2025
11 months ago benzinga.com
What to Expect from Abeona Therapeutics's Earnings
What to Expect from Abeona Therapeutics's Earnings
-
1 year ago benzinga.com
Abeona Secures Permanent CMS J-Code J3389 For ZEVASKYN Gene Therapy In Recessive Dystrophic Epidermolysis Bullosa; New J-Code Becomes Effective January 1, 2026
Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that the Centers for Medicare and…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
1 year ago benzinga.com
PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
1 year ago benzinga.com
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session